Last reviewed · How we verify
NCT05604989
Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration
Phase 3 trial testing Probiotic Combination Cap/Tab in Neovascular Age-related Macular Degeneration in 45 participants. Completed in 30 November 2024.
31 August 2024
Quick facts
| Lead sponsor | Seoul National University Bundang Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 45 |
| Start date | 1 January 2023 |
| Primary completion | 31 August 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Probiotic Combination Cap/Tab — full drug profile →
- intravitreal Anti-VEGF injection — full drug profile →
Conditions studied
- Neovascular Age-related Macular Degeneration — all drugs for Neovascular Age-related Macular Degeneration →
Sponsor
Seoul National University Bundang Hospital
Who can join
40 and older, any sex, with Neovascular Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A pilot study for Associations between the oral and intestinal microbiome and neovascular age-related macular degeneration and the investigation on the effect of oral probiotics as a treatment The investigators recruit the neovascular AMD patients and control patients. 1. 15 neovascular AMD patients with anti-VEGF treatment and oral probiotics supplement 2. 15 neovascular AMD patients with anti-VEGF treatment and no oral probiotics supplement 3. 15 control patients and no oral probiotics supplement The investigators will collect stool, blood, and saliva sample at the baseline and 6 months, and analyze the oral and intestinal microbiome changes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05604989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neovascular Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD · Phase 2 · recruiting
- NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
- NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients · EARLY_PHASE1 · recruiting
- NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
- NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R · Phase 3 · active not recruiting
Other Seoul National University Bundang Hospital trials
Trials by the same sponsor.
- NCT07459725 — Comparison of EEG-Timed vs. Repetitive Robot Therapy for Chronic Stroke · NA · not yet recruiting
- NCT07455279 — Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study · not yet recruiting
- NCT07477574 — Muscle-Specific Multimodal AI for Sarcopenia Diagnosis · NA · not yet recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07305662 — Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGU · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05604989 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Bundang Hospital
- Last refreshed: 16 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05604989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing